7-bromo-4-methyl-2H-benzo[b][1,4]thiazin-3(4H)-one | 1254319-46-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 7-bromo-4-methyl-2H-benzo[b][1,4]thiazin-3(4H)-one
• 英文别名: 7-Bromo-4-methyl-1,4-benzothiazin-3-one
• CAS: 1254319-46-4
• 化学式: C₉H₈BrNOS
• 分子量: 258.139
• InChiKey: QVSWOOUTHHRNKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-bromo-4-methyl-2H-benzo[b][1,4]thiazin-3(4H)-one 、 (S)-tert-butyl 4-(1-amino-1-oxo-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-ylcarbamoyl)tetrahydro-2H-pyran-4-ylcarbamate 在 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) sodium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 54.0h， 生成 (S)-tert-butyl 4-(1-amino-3-(4-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)phenyl)-1-oxopropan-2-ylcarbamoyl)tetrahydro-2H-pyran-4-ylcarbamate
  参考文献：
  名称：

  [EN] SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750
  [FR] COMPOSÉS 1-CYANOÉTHYLHÉTÉROCYCLYLCARBOXAMIDE SUBSTITUÉS 750

  摘要：

  本发明提供了式（I）的化合物，其中y、m、n、R1、R2和Q如规范中定义，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的用途。

  公开号：

  WO2010128324A1
• 作为产物：
  描述：

  7-溴-2H-[1,4]-苯并噻嗪-3(4H)-酮 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 1.0h， 生成 7-bromo-4-methyl-2H-benzo[b][1,4]thiazin-3(4H)-one
  参考文献：
  名称：

  [EN] SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750
  [FR] COMPOSÉS 1-CYANOÉTHYLHÉTÉROCYCLYLCARBOXAMIDE SUBSTITUÉS 750

  摘要：

  本发明提供了式（I）的化合物，其中y、m、n、R1、R2和Q如规范中定义，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的用途。

  公开号：

  WO2010128324A1

文献信息

• SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750
  申请人：Ford Rhonan

  公开号：US20100286118A1

  公开（公告）日：2010-11-11

  The present invention provides compounds of formula (I) in which y, m, n, R 1 , R 2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供式（I）的化合物，其中y，m，n，R1，R2和Q在说明书中定义，以及其制备过程，包含它们的制药组合物和它们在治疗中的使用。
• US8193239B2
  申请人：——

  公开号：US8193239B2

  公开（公告）日：2012-06-05
• [EN] PURINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS FOR PREVENTION OR TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS DE PURINE ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES POUR PRÉVENIR OU TRAITER LES INFECTIONS BACTÉRIENNES
  申请人：BIODIM LAB

  公开号：WO2012172043A1

  公开（公告）日：2012-12-20

  The invention relates to the compounds of general formula (I) and their addition salts thereof with acids and bases: wherein A is phenyl, naphthyl and 5-10 membered monocyclic or bicyclic unsaturated heterocycle, optionally substituted by a group R1 which is as defined in the application and is itself optionally substitutes by a group R2 which is as defined in the application and is itself optionally substituted by a group R3 which is defined in the application, Y and W, identical or different, are H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, phenyl or 4-10 monocyclic or bicyclic saturated or unsaturated heterocycle, optionally substituted by R1, or Y and/or W form a 4-10 membered cycle with R1, or Y and W form with N a saturated or unsaturated nitrogenous 4-10 membered mono, bi or tricyclic system, fused, bridged or spiro system, said system being optionally substituted by R1, said system being different from morpholine, with the proviso that when Y and A are phenyl or heterocycle, W is not H, a process and intermediates for their preparation and their use in the antibacterial prevention and therapy, used alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.
• [EN] SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750<br/>[FR] COMPOSÉS 1-CYANOÉTHYLHÉTÉROCYCLYLCARBOXAMIDE SUBSTITUÉS 750
  申请人：ASTRAZENECA AB

  公开号：WO2010128324A1

  公开（公告）日：2010-11-11

  The present invention provides compounds of formula (I), in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的化合物，其中y、m、n、R1、R2和Q如规范中定义，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的用途。